Organon & Co
XMUN:7XP

Watchlist Manager
Organon & Co Logo
Organon & Co
XMUN:7XP
Watchlist
Price: 7.162 EUR 2.96% Market Closed
Market Cap: 1.8B EUR

Gross Margin
Organon & Co

55%
Current
60%
Average
48.6%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
55%
=
Gross Profit
3.5B
/
Revenue
6.3B

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
US
Organon & Co
NYSE:OGN
2.2B USD
55%
US
Eli Lilly and Co
NYSE:LLY
966.6B USD
83%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
56%
US
Johnson & Johnson
NYSE:JNJ
523.5B USD
68%
CH
Roche Holding AG
SIX:ROG
276.2B CHF
74%
UK
AstraZeneca PLC
LSE:AZN
220.3B GBP
82%
CH
Novartis AG
SIX:NOVN
222.2B CHF
76%
US
Merck & Co Inc
NYSE:MRK
273.4B USD
79%
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK
82%
IE
Endo International PLC
LSE:0Y5F
213.9B USD
68%
US
Pfizer Inc
NYSE:PFE
144.7B USD
75%
No Stocks Found

Organon & Co
Glance View

In the corporate realm of healthcare, Organon & Co. emerged as a dedicated player with a mission to address vital needs in women's health. Born from a spin-off of Merck & Co.'s women's health, biosimilars, and established brands business in 2021, Organon positions itself at the heart of a neglected niche ripe with opportunity. The company's vision is clear: to enhance the health and well-being of women at every stage of life. Organon leverages its legacy of trusted brands while simultaneously developing new and innovative solutions that cater to female-specific health concerns. Through its robust portfolio of medicines and products, Organon focuses on conditions that resonate deeply with women's health issues, from contraception and fertility to postpartum recovery. As a biopharmaceutical company, it prides itself on combining a blend of established and emerging solutions to create sustainable value. Organon’s business model capitalizes on its diverse range of offerings, employing a three-pronged strategy. The women's health segment is a significant focus, providing products that are central in addressing previously unmet needs. Meanwhile, the biosimilars segment expands the company's reach, offering affordable alternatives to more costly biologic treatments, which is increasingly crucial in today's price-sensitive healthcare environment. Lastly, the established brands division comprises a portfolio of mature pharmaceutical products that continue to generate stable revenue, thanks partly to their enduring trust among healthcare professionals. This multifaceted approach ensures Organon isn't merely reliant on new product development but can also maximize value from existing assets. The synergy across these divisions allows Organon to not only meet current market demands but also anticipate future health trends, making it a dynamic entity in the global healthcare landscape.

7XP Intrinsic Value
44.133 EUR
Undervaluation 84%
Intrinsic Value
Price
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
55%
=
Gross Profit
3.5B
/
Revenue
6.3B
What is the Gross Margin of Organon & Co?

Based on Organon & Co's most recent financial statements, the company has Gross Margin of 55%.

Back to Top